Cervical cancer vaccines: Recent advances in HPV research

Gretchen L. Eiben, Diane M. Da Silva, Steven C. Fausch, I. Caroline Le Poole, Michael I. Nishimura, W. Martin Kast*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

63 Scopus citations


Carcinomas of the anogenital tract, particularly cancer of the cervix, account for almost 12% of all cancers in women, and so represent the second most frequent gynecological malignancy in the world (48). It is well established that chronic infection of cervical epithelium by human papillomaviruses (HPV) is necessary for the development of cervical cancer. In fact, HPV DNA has been demonstrated in more than 99.7% of cervical cancer biopsy specimens, with high-risk HPV16 and HPV18 sequences being most prevalent (45,73). Therefore, an effective vaccine that would mount an immune response against HPV-related proteins might contribute to the prevention or elimination of HPV expressing lesions. This review will concentrate on the most recent advances in vaccine-mediated prevention and immunotherapy of HPV-induced cervical cancer, including presentations from the 20th International HPV Conference held in October 2002 in Paris.

Original languageEnglish (US)
Pages (from-to)111-121
Number of pages11
JournalViral Immunology
Issue number2
StatePublished - 2003

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Virology

Fingerprint Dive into the research topics of 'Cervical cancer vaccines: Recent advances in HPV research'. Together they form a unique fingerprint.

Cite this